Leishmaniasis: Clinical Trials

8 trials for Leishmaniasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 terminated. 8 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 28Terminated 8
Phase 11Terminated 1
Phase 31Terminated 1

Follow Leishmaniasis: new trials by email Literature Review of Leishmaniasis trials Research Report on Leishmaniasis

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan
Fexinidazole - Visceral Leishmaniasis
Phase 2TerminatedDrugs for Neglected Diseases142013-11-012015-10-30
Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis
WR 279,396 - Leishmaniasis, Cutaneous
Phase 2TerminatedU.S. Army Medical Research and Development Command12013-09-012019-11-22
WR 279,396 Open Label Treatment Protocol in Tunisia
WR 279,396 topical cream - Cutaneous Leishmaniasis
Phase 2TerminatedU.S. Army Medical Research and Development Command502011-12-012014-12-19
Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL
Liposomal amphotericin B (Ambisome) - Visceral Leishmaniasis
Phase 2TerminatedDrugs for Neglected Diseases1242009-04-012016-01-21
Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis
Glucantime®, Zithromax ® - Cutaneous Leishmaniasis
Phase 2 / Phase 3TerminatedAna Rabello482008-06-012014-10-17
Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony
Miltefosine and antimony, Miltefosine alone - Cutaneous Leishmaniasis
Phase 2TerminatedFoundation Fader192007-03-012011-06-27
Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396
Paromomycin +Gentamicin topical cream - Cutaneous Leishmaniasis
Phase 2TerminatedU.S. Army Medical Research and Development Command12006-12-202019-01-22
Miltefosine for Brazilian Visceral Leishmaniasis
Miltefosine: initially 2.5 mg/kg/day for 28 days - Kala Azar
Phase 1 / Phase 2TerminatedAB Foundation802005-04-012016-07-12

Narrower conditions

Leishmaniasis, Cutaneous (5)  ·  Leishmaniasis, Visceral (3)

Broader conditions

Euglenozoa Infections (8)  ·  Infections (8)  ·  Parasitic Diseases (8)  ·  Protozoan Infections (8)  ·  Vector Borne Diseases (8)  ·  Skin Diseases (5)  ·  Skin Diseases, Infectious (5)  ·  Skin Diseases, Parasitic (5)  ·  Skin and Connective Tissue Diseases (5)

Interventions

Paromomycin (2)  ·  Antimony (1)  ·  Azithromycin (1)  ·  Meglumine Antimoniate (1)  ·  fexinidazole (1)  ·  liposomal amphotericin B (1)  ·  miltefosine (1)

Sponsors

U.S. Army Medical Research and Development Command (3)  ·  Drugs for Neglected Diseases (2)  ·  AB Foundation (1)  ·  Ana Rabello (1)  ·  Foundation Fader (1)

Countries

Brazil (2)  ·  Sudan (2)  ·  United States (2)  ·  Bolivia (1)  ·  Ethiopia (1)  ·  Tunisia (1)

Top investigators

Afif Ben Salah, M.D., Ph.D. (1)  ·  Ahmed M Musa, MD PhD (1)  ·  Ana Rabello, MD PhD (1)  ·  E. AG Khalil, Prof. MD (1)  ·  Isabela Ribeiro, MD (1)  ·  Reynaldo Dietze (1)  ·  Sisay Yifru, MD (1)  ·  Timothy Whitman, DO, USN (1)

Results publications

PMID 21375777, PMID 24454970